Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer

Edoardo Isnaldi, Anna Garuti, Gabriella Cirmena, Stefano Scabini, Edoardo Rimini, Lorenzo Ferrando, Michela Lia, Roberto Murialdo, Lucia Tixi, Enrico Carminati, Andrea Panaro, Maurizio Gallo, Federica Grillo, Luca Mastracci, Lazzaro Repetto, Roberto Fiocca, Emanuele Romairone, Gabriele Zoppoli, Alberto Ballestrero

Research output: Contribution to journalArticle

Abstract

Background: Over the past few years, next-generation sequencing (NGS) has become reliable and cost-effective, and its use in clinical practice has become a reality. A relevant role for NGS is the prediction of response to anti-EGFR agents in metastatic colorectal cancer (mCRC), where multiple exons from KRAS, NRAS, and BRAF must be sequenced simultaneously. Methods: We optimized a 14-amplicon NGS panel to assess, in a consecutive cohort of 219 patients affected by mCRC, the presence and clinico-pathological associations of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes from formalin-fixed, paraffin-embedded specimens collected for diagnostics and research at the time of diagnosis. Results: We observed a statistically significant association of RAS mutations with sex, young age, and tumor site. We demonstrated that concomitant mutations in the RAS/RAF pathway are not infrequent in mCRC, and as anticipated by whole-genome studies, RAS and PIK3CA tend to be concurrently mutated. We corroborated the association of BRAF mutations in right mCRC tumors with microsatellite instability. We established tumor side as prognostic parameter independently of mutational status. Conclusions: To our knowledge, this is the first monocentric, consecutively accrued clinical mCRC cancer cohort tested by NGS in a real-world context for KRAS, NRAS, BRAF, and PIK3CA. Our study has highlighted in clinical practice findings such as the concomitance of mutations in the RAS/RAF pathway, the presence of multiple mutations in single gene, the co-occurrence of RAS and PIK3CA mutations, the prognostic value of tumor side and possible associations of sex with specific mutations.

Original languageEnglish
Article number137
JournalJournal of Translational Medicine
Volume17
Issue number1
DOIs
Publication statusPublished - Apr 29 2019

Fingerprint

Tumors
Colorectal Neoplasms
Mutation
Genes
Paraffin
Microsatellite Repeats
Formaldehyde
Exons
Neoplasms
Microsatellite Instability
Costs
Genome
Costs and Cost Analysis
Research

Keywords

  • Anti-EGFR
  • Concomitant mutations
  • Extended RAS
  • Metastatic colorectal cancer
  • RAS/RAF pathway

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. / Isnaldi, Edoardo; Garuti, Anna; Cirmena, Gabriella; Scabini, Stefano; Rimini, Edoardo; Ferrando, Lorenzo; Lia, Michela; Murialdo, Roberto; Tixi, Lucia; Carminati, Enrico; Panaro, Andrea; Gallo, Maurizio; Grillo, Federica; Mastracci, Luca; Repetto, Lazzaro; Fiocca, Roberto; Romairone, Emanuele; Zoppoli, Gabriele; Ballestrero, Alberto.

In: Journal of Translational Medicine, Vol. 17, No. 1, 137, 29.04.2019.

Research output: Contribution to journalArticle

Isnaldi, E, Garuti, A, Cirmena, G, Scabini, S, Rimini, E, Ferrando, L, Lia, M, Murialdo, R, Tixi, L, Carminati, E, Panaro, A, Gallo, M, Grillo, F, Mastracci, L, Repetto, L, Fiocca, R, Romairone, E, Zoppoli, G & Ballestrero, A 2019, 'Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer', Journal of Translational Medicine, vol. 17, no. 1, 137. https://doi.org/10.1186/s12967-019-1879-2
Isnaldi, Edoardo ; Garuti, Anna ; Cirmena, Gabriella ; Scabini, Stefano ; Rimini, Edoardo ; Ferrando, Lorenzo ; Lia, Michela ; Murialdo, Roberto ; Tixi, Lucia ; Carminati, Enrico ; Panaro, Andrea ; Gallo, Maurizio ; Grillo, Federica ; Mastracci, Luca ; Repetto, Lazzaro ; Fiocca, Roberto ; Romairone, Emanuele ; Zoppoli, Gabriele ; Ballestrero, Alberto. / Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. In: Journal of Translational Medicine. 2019 ; Vol. 17, No. 1.
@article{d9132b8fb7694fe9a701fbb08c9849bf,
title = "Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer",
abstract = "Background: Over the past few years, next-generation sequencing (NGS) has become reliable and cost-effective, and its use in clinical practice has become a reality. A relevant role for NGS is the prediction of response to anti-EGFR agents in metastatic colorectal cancer (mCRC), where multiple exons from KRAS, NRAS, and BRAF must be sequenced simultaneously. Methods: We optimized a 14-amplicon NGS panel to assess, in a consecutive cohort of 219 patients affected by mCRC, the presence and clinico-pathological associations of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes from formalin-fixed, paraffin-embedded specimens collected for diagnostics and research at the time of diagnosis. Results: We observed a statistically significant association of RAS mutations with sex, young age, and tumor site. We demonstrated that concomitant mutations in the RAS/RAF pathway are not infrequent in mCRC, and as anticipated by whole-genome studies, RAS and PIK3CA tend to be concurrently mutated. We corroborated the association of BRAF mutations in right mCRC tumors with microsatellite instability. We established tumor side as prognostic parameter independently of mutational status. Conclusions: To our knowledge, this is the first monocentric, consecutively accrued clinical mCRC cancer cohort tested by NGS in a real-world context for KRAS, NRAS, BRAF, and PIK3CA. Our study has highlighted in clinical practice findings such as the concomitance of mutations in the RAS/RAF pathway, the presence of multiple mutations in single gene, the co-occurrence of RAS and PIK3CA mutations, the prognostic value of tumor side and possible associations of sex with specific mutations.",
keywords = "Anti-EGFR, Concomitant mutations, Extended RAS, Metastatic colorectal cancer, RAS/RAF pathway",
author = "Edoardo Isnaldi and Anna Garuti and Gabriella Cirmena and Stefano Scabini and Edoardo Rimini and Lorenzo Ferrando and Michela Lia and Roberto Murialdo and Lucia Tixi and Enrico Carminati and Andrea Panaro and Maurizio Gallo and Federica Grillo and Luca Mastracci and Lazzaro Repetto and Roberto Fiocca and Emanuele Romairone and Gabriele Zoppoli and Alberto Ballestrero",
year = "2019",
month = "4",
day = "29",
doi = "10.1186/s12967-019-1879-2",
language = "English",
volume = "17",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer

AU - Isnaldi, Edoardo

AU - Garuti, Anna

AU - Cirmena, Gabriella

AU - Scabini, Stefano

AU - Rimini, Edoardo

AU - Ferrando, Lorenzo

AU - Lia, Michela

AU - Murialdo, Roberto

AU - Tixi, Lucia

AU - Carminati, Enrico

AU - Panaro, Andrea

AU - Gallo, Maurizio

AU - Grillo, Federica

AU - Mastracci, Luca

AU - Repetto, Lazzaro

AU - Fiocca, Roberto

AU - Romairone, Emanuele

AU - Zoppoli, Gabriele

AU - Ballestrero, Alberto

PY - 2019/4/29

Y1 - 2019/4/29

N2 - Background: Over the past few years, next-generation sequencing (NGS) has become reliable and cost-effective, and its use in clinical practice has become a reality. A relevant role for NGS is the prediction of response to anti-EGFR agents in metastatic colorectal cancer (mCRC), where multiple exons from KRAS, NRAS, and BRAF must be sequenced simultaneously. Methods: We optimized a 14-amplicon NGS panel to assess, in a consecutive cohort of 219 patients affected by mCRC, the presence and clinico-pathological associations of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes from formalin-fixed, paraffin-embedded specimens collected for diagnostics and research at the time of diagnosis. Results: We observed a statistically significant association of RAS mutations with sex, young age, and tumor site. We demonstrated that concomitant mutations in the RAS/RAF pathway are not infrequent in mCRC, and as anticipated by whole-genome studies, RAS and PIK3CA tend to be concurrently mutated. We corroborated the association of BRAF mutations in right mCRC tumors with microsatellite instability. We established tumor side as prognostic parameter independently of mutational status. Conclusions: To our knowledge, this is the first monocentric, consecutively accrued clinical mCRC cancer cohort tested by NGS in a real-world context for KRAS, NRAS, BRAF, and PIK3CA. Our study has highlighted in clinical practice findings such as the concomitance of mutations in the RAS/RAF pathway, the presence of multiple mutations in single gene, the co-occurrence of RAS and PIK3CA mutations, the prognostic value of tumor side and possible associations of sex with specific mutations.

AB - Background: Over the past few years, next-generation sequencing (NGS) has become reliable and cost-effective, and its use in clinical practice has become a reality. A relevant role for NGS is the prediction of response to anti-EGFR agents in metastatic colorectal cancer (mCRC), where multiple exons from KRAS, NRAS, and BRAF must be sequenced simultaneously. Methods: We optimized a 14-amplicon NGS panel to assess, in a consecutive cohort of 219 patients affected by mCRC, the presence and clinico-pathological associations of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes from formalin-fixed, paraffin-embedded specimens collected for diagnostics and research at the time of diagnosis. Results: We observed a statistically significant association of RAS mutations with sex, young age, and tumor site. We demonstrated that concomitant mutations in the RAS/RAF pathway are not infrequent in mCRC, and as anticipated by whole-genome studies, RAS and PIK3CA tend to be concurrently mutated. We corroborated the association of BRAF mutations in right mCRC tumors with microsatellite instability. We established tumor side as prognostic parameter independently of mutational status. Conclusions: To our knowledge, this is the first monocentric, consecutively accrued clinical mCRC cancer cohort tested by NGS in a real-world context for KRAS, NRAS, BRAF, and PIK3CA. Our study has highlighted in clinical practice findings such as the concomitance of mutations in the RAS/RAF pathway, the presence of multiple mutations in single gene, the co-occurrence of RAS and PIK3CA mutations, the prognostic value of tumor side and possible associations of sex with specific mutations.

KW - Anti-EGFR

KW - Concomitant mutations

KW - Extended RAS

KW - Metastatic colorectal cancer

KW - RAS/RAF pathway

UR - http://www.scopus.com/inward/record.url?scp=85065227542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065227542&partnerID=8YFLogxK

U2 - 10.1186/s12967-019-1879-2

DO - 10.1186/s12967-019-1879-2

M3 - Article

C2 - 31036005

AN - SCOPUS:85065227542

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 137

ER -